EyeSol® is the worldwide first and only water-free technology for ophthalmic products. It dramatically increases the residual time on the eye from minutes to hours and enables high bioavailability of active pharmaceutical ingredients (API) with excellent tolerability and safety while reducing systemic exposure due to a small drop size (10 µL).
Thereby EyeSol® unlocks the full potential of APIs by generating novel drug products often even with new Composition of Matter IP. The technology is clinically validated, safe and well accepted.
|Program||Drug Indication||Disc.||Pre-clinic||Phase I||Phase II||Phase III||Reg.||Market||Milestones|
|CyclASol® (cyclosporine A)||Dry Eye Disease, anti-inflammatory||
ESSENCE-2 top line data in 2021;
US NDA submission 2022
|NOV03 (perfluorohexyloctane)||Dry Eye Disease, associated with MGD*||
Developed by: Bausch+Lomb (USA);
Hengrui Medicine (China)
|BTQ 1901 / BTQ 1902 (timolol, nebivolol)||Glaucoma, beta-blockers||USA||
US clinical phase starts in 2021;
Developed with Betaliq Inc.
|Program||CyclASol® (cyclosporine A)||NOV03 (perfluorohexyloctane)||BTQ 1901 / BTQ 1902 (timolol, nebivolol)|
|Drug Indication||Dry Eye Disease, anti-inflammatory||Dry Eye Disease, associated with MGD||Glaucoma, beta-blockers|
|Market||USA, CHN||USA, CHN||USA|
|Milestones||ESSENCE-2 top line data 2021; US NDA submission 2022||Developed by: Bausch+Lomb (USA); Hengrui Medicine (China)||US clinical phase starts in 2021; Developed with Betaliq Inc.|
* MGD = Meibomian Gland Dysfunction